secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucy Scientific Discovery, Inc. (—)
CIK:        0001865127
Form:       8-K
Filed at:   2023-07-07T23:59:59+00:00
Accession:  0001213900-23-055368
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 2.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucy Scientific completes acquisition of Wesana's SANA-013 assets; forms Lucy Discoveries Holdings
--------------------------------------------------------------------------------

- Acquired SANA-013, a psilocybin/CBD combination therapy for MDD, migraine, cluster headaches, and trigeminal neuralgia.
- Consideration: $300K cash, $177,974 in installments through April 2024, 1M common shares, and assumption of $92K debt.
- Formed Lucy Discoveries Holdings to advance psychedelic medicine R&D and diversify its therapy pipeline.
- Wesana CEO Daniel Carcillo will join Lucy; transaction closed June 30, 2023, press release dated July 5.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865127/000121390023055368/0001213900-23-055368-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865127/000121390023055368/ea181425-8k_lucyscien.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-055368

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer